Lundbeck has received Fast Track designation from the U.S. FDA for Lu AH69593, its lead oral orexin 2 receptor agonist in ...
GSK has secured US FDA approval for Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1‑positive ...
First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...
Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...
Jasper Therapeutics has completed its all‑stock acquisition of Kira Pharmaceuticals, creating a combined business focused on ...
Nouscom will present new phase 1b/2 data on its off‑the‑shelf cancer immunotherapy NOUS‑209 at the European Society for ...
Ardena has appointed Ariane de Ganck as Chief Scientific Officer, reinforcing its focus on scientific excellence across its ...
ViiV Healthcare will present a broad range of clinical and real-world data at AIDS 2026, highlighting progress across its integrase strand transfer inhibitor portfolio, including long-acting medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results